治疗遗传性血管水肿新药艾替班特的药理作用与临床研究新进展  

Progress in pharmacological and clinical study of icatibant,a new drug for the treatment of hereditary angioedema

作　　者：刘雪松[1] 刘冰洋[2] 王京晶[2] 宋冬梅[2] 

机构地区：[1]辽宁中医药大学附属第二医院,沈阳110034 [2]沈阳亿灵医药科技有限公司,沈阳110179

出　　处：《中国新药杂志》2012年第4期351-354,共4页Chinese Journal of New Drugs

摘　　要：艾替班特作为缓激肽B2受体抑制剂,对18岁及以上成人遗传性血管水肿(HAE)急性发作具有很好的疗效,且不良反应较少,可由患者自助给药,便于携带及紧急情况下使用。本文利用MEDLINE对关键词艾替班特、缓激肽B2受体抑制剂和HAE进行检索,并对检索到的体外、体内试验结果进行综述,通过文献回顾了艾替班特在治疗HAE中的作用机制、药效学、药代动力学、临床评价和安全性,更多的研究有待进一步评价。Icatibant is a potent bradykinin B2 receptor antagonist for the treatment of acute attacks of hereditary angioedema（HAE） in 18-years-old and older adults.It is convenient for patients to self-administering icatibant upon recognition of HAE attack symptoms after training.References of in vitro and in vivo studies evaluating icatibant were obtained from MEDLINE to review the action mechanism,pharmacodynamics,pharmacokinetics,clinical evaluation,and safety of icatibant in the treatment of HAE.The key terms used in database searches were icatibant,bradykinin B2 receptor antagonist,hereditary angioedema and HAE.Icatibant is effective and generally well tolerated in patients with acute HAE attacks.However,more research is required to solidify icatibant therapy.

关 键 词：艾替班特 遗传性血管水肿 缓激肽B2受体抑制剂 

分 类 号：R973[医药卫生—药品]